Partial agonists for A3 adenosine receptors

Current Topics in Medicinal Chemistry

Volumn 4, Issue 8, 2004, Pages 855-862

  Gao, Zhan Guo ^a   Jacobson, Kenneth A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 6 N CYCLOPENTYLADENOSINE; 2 CHLOROADENOSINE; 2 CHLOROPHENYLISOPROPYLADENOSINE; 2 DEOXY 6 N CYCLOPENTYLADENOSINE; 2 FLUOROADENOSINE; 2 IODO 6 N (2 ENDONORBORN 2 YL)ADENOSINE; 5 [6 [(OXOLAN 3 YL)AMINO]PURIN 9 YL] 3,4 DIHYDROXYOXOLAN 2 YL METHOXY N METHYLCARBOXAMIDE; 6 N [2 (3,5 DIMETHOXYPHENYL) 2 (2 METHYLPHENYL)ETHYL]ADENOSINE; 6 N BENZYLADENOSINE; 6 N CYCLOPENTYLADENOSINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A2A RECEPTOR AGONIST; ADENOSINE A3 RECEPTOR; ADENOSINE A3 RECEPTOR AGONIST; ADENOSINE A3 RECEPTOR ANTAGONIST; ADENOSINE DERIVATIVE; BENZENE DERIVATIVE; CVT 2759; CYCLIC AMP; FORSKOLIN; METHYL GROUP; MRS 1743; MRS 1898; MRS 1939; MRS 542; OXYGEN; PHENYLISOPROPYLADENOSINE; RECEPTOR SUBTYPE; RIBOSE; THIOL GROUP; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BINDING AFFINITY; BRAIN ISCHEMIA; CHEMICAL MODIFICATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; HEART MUSCLE ISCHEMIA; HUMAN; INTERMETHOD COMPARISON; NONHUMAN; REVIEW; SPECIES DIFFERENCE; STRUCTURE ACTIVITY RELATION;

ADENINE; ADENOSINE; ANIMALS; HUMANS; LIGANDS; RECEPTOR, ADENOSINE A3; RIBOSE; STRUCTURE-ACTIVITY RELATIONSHIP; XANTHINE;

EID: 3042723245     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026043450989     Document Type: Review

References (34)

1. Fredholm, B.B.; IJzerman, A.P.; Jacobson, K.A.; Klotz, K.N.; Linden, J. International Union of Pharmacology. XXV. Nomenclature and classification of ARs. Pharmacol. Rev. 2001, 53, 527-552.
2. 6-cyclopentyladenosine in the rat. J. Pharmacol. Exp. Ther. 1994, 268, 616-624.
3. Danhof, M.; Mandema, J.W.; Hoogerkamp, A.; Mathot, R.A. Pharmacokinetic-pharmacodynamic modeling in pre-clinical investigations: principles and perspectives. Eur. J. Drug. Metab. Pharmacokinet. 1993, 18, 41-47.
4. 1-AR selectively slows AV conduction in guinea pig hearts. Am. J. Physiol. Heart Circ. Physiol. 2001, 280, H334-H343.
5. Barlow, J.J.; Main, B.G.; Snow, H.M. Beta-adrenoceptor stimulant properties of amidoalkylamino-substituted 1-aryl-2-ethanols and 1-(aryloxy)-2-propanols. J. Med. Chem. 1981, 24, 315-322.
6. IJzerman, A.P.; van der Wenden, E.M.; von Frijtag Drabbe Künzel, J.K.; Mathot, R.A.; Danhof, M.; Borea, P.A.; Varani, K. Partial agonism of theophylline-7-riboside on adenosine receptors. Naunyn Schmiedebergs Arch. Pharmacol. 1994, 350, 638-645.
7. 6-cyclopentyladenosine (CPA): partial agonists at the adenosine A1 receptor in vivo. Br. J. Pharmacol. 1995, 116, 1957-1964.
8. 1 receptor. J. Med. Chem. 1998, 41, 102-108.
9. 2-ARs coupled to adenylate cyclase. Biochem. Pharmacol. 1992, 43, 1089-1093.
10. 3 receptor. J. Med. Chem. 2002, 45, 420-429.
11. 2A receptor. Bioorg. Med. Chem. 2003, 11, 2183-2192.
12. 1 adenosine receptor agonists. Bioorg. Med. Chem. 2002, 10, 1115-1122.
13. 3 adenosine receptor activation: Nucleoside ligands at the agonist/antagonist boundary. J. Med. Chem. 2002, 45, 4471-4484.
14. 3 receptor. Eur. J. Pharmacol. 2002, 443, 39-42.
15. 3 adenosine receptors. Biochem. Pharmacol. 2003, 65, 1675-1684
16. 3 adenosine receptors: Modification of the ribose moiety. Biochem. Pharmacol. 2004, 67, 893-901.
17. 3 receptor. J. Med. Chem. 1999, 42, 1393-1400.
18. 3 receptors. J. Med. Chem. 2001, 44, 2966-2975.
19. 3-adenosine receptors. J. Med. Chem. 1994, 37, 3614-3621.
20. 1 receptors. J. Med. Chem. 1996, 39, 1463-1471.
21. 6-cyclopentyladenosine in vivo: haemodynamic versus anti-lipolytic responses in rats. Br. J. Pharmacol. 1998, 124, 607-618.
22. 3 adenosine receptor. Mol. Pharmacol. 1994, 45, 1101-1111.
23. Kenakin, T.P. The Pharmacologic Analysis of Drug-Receptor Interactions. LIPPINCOTT-Raven, Philadelphia, 1997.
24. 3 selective ligands containing bioisosteric isoxazoles. Bioorg. Med. Chem. Lett. 1998, 8, 1767-1770.
25. van der Wenden, E.M.; von Frijtag Drabbe Künzel, J.K.; Mathot, R.A.; Danhof, M.; IJzerman, A.P.; Soudijn, W. Robose-modified adenosine analogues as potential partial agonists for the AR. J. Med. Chem. 1995, 38, 4000-4006.
26. 1 adenosine receptors. Naunyn Schmiedebergs Arch. Pharmacol. 1988, 337, 687-689.
27. 3 receptor ligands. Bioorg. Med. Chem. Lett. 2003, 13, 817-820.
28. 3 adenosine receptor. J. Med. Chem. in press.
29. 3 adenosine receptors. J. Med. Chem. 1995, 38, 1720-1735
30. Jacobson KA, Ji X, Li AH, Melman N, Siddiqui MA, Shin KJ, Marquez VE, Ravi RG. Methanocarba analogues of purine nucleosides as potent and selective AR agonists. J. Med. Chem. 2000, 43, 2196-2203.
31. Jacobson, K.A.; Ji, X.; Li, A.H.; Melman, N.; Siddiqui, M.A.; Shin, K.J.; Marquez, V.E.; Ravi, R.G. Methanocarba analogues of purine nucleosides as potent and selective AR agonists. J. Med. Chem. 2000, 43, 2196-2203.
32. Lee, K.; Ravi, G.; Ji, X.D.; Marquez, V.E.; Jacobson, K.A. Ring-Constrained (N)-methanocarba nucleosides as adenosine receptor agonists: independent 5′-uronamide and 2′-deoxy modifications. Bioorg. Med. Chem. Lett. 2001, 11, 1333-1337.
33. Bridson, P.K.; Lin, X.; Melman, N.; Ji, X.D.; Jacobson, K.A. Synthesis and AR affinity of 7-β-D-ribofuranosylxanthine. Nucleosides Nucleotides. 1998, 17, 759-768.
34. 3 adenosine receptors: structure-activity relationships of 1,3-dialkylxanthine 7-riboside derivatives. J. Med. Chem. 1994, 37, 4020-4030.